Abstract
Background: Systolic dysfunction in heart failure (HF) predicts increased rates of morbidity and mortality. Nesiritide (NES) has been used for the acute treatment of HF. The safety, tolerability, and clinical effects of serial outpatient infusions of NES were recently evaluated in the FUSION study. This analysis examines the effect of NES on myocardial performance in patients (pts) within the FUSION trial with a baseline ejection fraction (EF) ≤40%.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
